• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    General Counsel Watson David O. sold $139,789 worth of shares (5,569 units at $25.10), gifted 6,667 shares and received a gift of 6,667 shares, decreasing direct ownership by 4% to 138,730 units (SEC Form 4)

    3/6/25 5:17:05 PM ET
    $APLS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $APLS alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Watson David O.

    (Last) (First) (Middle)
    C/O APELLIS PHARMACEUTICALS, INC
    100 FIFTH AVENUE, 3RD FLOOR

    (Street)
    WALTHAM MA 02451

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Apellis Pharmaceuticals, Inc. [ APLS ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director 10% Owner
    X Officer (give title below) Other (specify below)
    General Counsel
    3. Date of Earliest Transaction (Month/Day/Year)
    03/04/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 03/04/2025 G(1) 6,667 D $0 0 I(2) Indirect Owner (The Watson Education Trust)
    Common Stock 03/04/2025 G(1) 6,667 A $0 10,000 I(3) Indirect Owner (Custodial Account for Son)
    Common Stock 03/05/2025 S 5,569 D $25.1013 138,730 D
    Common Stock 70,136 I(4) Indirect Owner (The David O. Watson Irrevocable Trust of 2023)
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    1. Reflects the transfer for no value of shares from the Watson Education Trust to a custodial account held by the reporting person for the sole benefit of his minor son on March 4, 2025.
    2. The securities are held by the Watson Education Trust, for which the reporting person serves as trustee. The reporting person disclaims beneficial ownership over the shares held by the Education Trust except to the extent of his pecuniary interest therein.
    3. This represents a custodial account held by the reporting person for the sole benefit of his minor son.
    4. The securities are held by The David O. Watson Irrevocable Trust of 2023. William Zorn is the trustee of The David O. Watson Irrevocable Trust of 2023. The reporting person disclaims beneficial ownership over the shares held by The David O. Watson Irrevocable Trust of 2023 except to the extent of his pecuniary interest therein.
    David Watson 03/06/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $APLS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $APLS

    DatePrice TargetRatingAnalyst
    5/9/2025$23.00Buy → Neutral
    BofA Securities
    5/9/2025$52.00Strong Buy → Outperform
    Raymond James
    4/29/2025$44.00Overweight
    Cantor Fitzgerald
    12/17/2024$36.00Buy → Neutral
    Goldman
    11/21/2024$31.00Equal-Weight
    Morgan Stanley
    10/25/2024$25.00Sector Perform
    RBC Capital Mkts
    10/16/2024Sector Outperform
    Scotiabank
    10/16/2024Outperform
    William Blair
    More analyst ratings

    $APLS
    SEC Filings

    See more
    • SEC Form 10-Q filed by Apellis Pharmaceuticals Inc.

      10-Q - Apellis Pharmaceuticals, Inc. (0001492422) (Filer)

      5/7/25 7:01:36 AM ET
      $APLS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by Apellis Pharmaceuticals Inc.

      DEFA14A - Apellis Pharmaceuticals, Inc. (0001492422) (Filer)

      4/23/25 7:35:44 AM ET
      $APLS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEF 14A filed by Apellis Pharmaceuticals Inc.

      DEF 14A - Apellis Pharmaceuticals, Inc. (0001492422) (Filer)

      4/23/25 7:33:44 AM ET
      $APLS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $APLS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Apellis Pharmaceuticals downgraded by Raymond James with a new price target

      Raymond James downgraded Apellis Pharmaceuticals from Strong Buy to Outperform and set a new price target of $52.00

      5/9/25 8:40:54 AM ET
      $APLS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Apellis Pharmaceuticals downgraded by BofA Securities with a new price target

      BofA Securities downgraded Apellis Pharmaceuticals from Buy to Neutral and set a new price target of $23.00

      5/9/25 8:40:54 AM ET
      $APLS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cantor Fitzgerald initiated coverage on Apellis Pharmaceuticals with a new price target

      Cantor Fitzgerald initiated coverage of Apellis Pharmaceuticals with a rating of Overweight and set a new price target of $44.00

      4/29/25 8:10:45 AM ET
      $APLS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $APLS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $APLS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    $APLS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Director Wheeler Craig A was granted 16,483 shares (SEC Form 4)

      4 - Apellis Pharmaceuticals, Inc. (0001492422) (Issuer)

      4/21/25 4:23:01 PM ET
      $APLS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 3 filed by new insider Wheeler Craig A

      3 - Apellis Pharmaceuticals, Inc. (0001492422) (Issuer)

      4/21/25 4:09:13 PM ET
      $APLS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • VP/Chief Accounting Officer Chopas James George sold $4,543 worth of shares (183 units at $24.82), decreasing direct ownership by 0.38% to 47,955 units (SEC Form 4)

      4 - Apellis Pharmaceuticals, Inc. (0001492422) (Issuer)

      3/18/25 12:27:02 PM ET
      $APLS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Apellis Pharmaceuticals Inc.

      SC 13G/A - Apellis Pharmaceuticals, Inc. (0001492422) (Subject)

      11/22/24 4:16:13 PM ET
      $APLS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Apellis Pharmaceuticals Inc.

      SC 13G - Apellis Pharmaceuticals, Inc. (0001492422) (Subject)

      11/22/24 8:47:59 AM ET
      $APLS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Apellis Pharmaceuticals Inc.

      SC 13G/A - Apellis Pharmaceuticals, Inc. (0001492422) (Subject)

      11/14/24 1:28:32 PM ET
      $APLS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Apellis Pharmaceuticals Reports First Quarter 2025 Financial Results

      Generated $166.8 million in 1Q 2025 revenues, including $149.9 million in U.S. net product salesSYFOVRE® (pegcetacoplan injection) injection demand grew 4% quarter-over-quarter, with U.S. net product revenue of $130.2 million Increase in demand offset by inventory dynamics and funding shortages at co-pay assistance programs Received U.S. FDA filing acceptance of supplemental new drug application (sNDA) with Priority Review designation for EMPAVELI for treatment of C3G and primary IC-MPGNOn track to initiate two pivotal trials of EMPAVELI in focal segmental glomerulosclerosis (FSGS) and in delayed graft function (DGF) in 2H 2025Cash and cash equivalents of $358.4 million as of March 31, 2025;

      5/7/25 7:00:00 AM ET
      $APLS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Apellis Pharmaceuticals to Present at Upcoming Investor Conferences

      WALTHAM, Mass., May 06, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) today announced that the company will participate in the following May investor conferences: BofA Securities 2025 Healthcare Conference: Fireside chat on Tuesday, May 13, 2025 at 8:40 a.m. PTStifel 2025 Virtual Ophthalmology Forum: Fireside chat on Tuesday, May 27, 2025 at 2:30 p.m. ET The live conference webcasts will be posted on the "Events and Presentations" page of the "Investors and Media" section of the company's website. A replay of the webcasts will be available for approximately 90 days following the event. About ApellisApellis Pharmaceuticals, Inc. is a global biopharmaceutical compan

      5/6/25 7:00:00 AM ET
      $APLS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Apellis Pharmaceuticals to Host Conference Call on May 7, 2025, to Discuss First Quarter 2025 Financial Results

      WALTHAM, Mass., April 30, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) today announced that the company will host a conference call and webcast to discuss its first quarter 2025 financial results on Wednesday, May 7, 2025, at 8:30 a.m. ET. To access the live call by phone, please pre-register for the call here. A live audio webcast of the event and accompanying slides may also be accessed through the "Events and Presentations" page of the "Investors and Media" section of the company's website. A replay of the webcast will be available for 90 days following the event. About Apellis Apellis Pharmaceuticals, Inc. is a global biopharmaceutical company that combines co

      4/30/25 7:00:00 AM ET
      $APLS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $APLS
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • FDA Approval for EMPAVELI issued to APELLIS PHARMACEUTICALS INC

      Submission status for APELLIS PHARMACEUTICALS INC's drug EMPAVELI (ORIG-1) with active ingredient PEGCETACOPLAN has changed to 'Approval' on 05/14/2021. Application Category: NDA, Application Number: 215014, Application Classification: Type 1 - New Molecular Entity

      5/17/21 11:09:40 AM ET
      $APLS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $APLS
    Financials

    Live finance-specific insights

    See more
    • Apellis Pharmaceuticals Reports First Quarter 2025 Financial Results

      Generated $166.8 million in 1Q 2025 revenues, including $149.9 million in U.S. net product salesSYFOVRE® (pegcetacoplan injection) injection demand grew 4% quarter-over-quarter, with U.S. net product revenue of $130.2 million Increase in demand offset by inventory dynamics and funding shortages at co-pay assistance programs Received U.S. FDA filing acceptance of supplemental new drug application (sNDA) with Priority Review designation for EMPAVELI for treatment of C3G and primary IC-MPGNOn track to initiate two pivotal trials of EMPAVELI in focal segmental glomerulosclerosis (FSGS) and in delayed graft function (DGF) in 2H 2025Cash and cash equivalents of $358.4 million as of March 31, 2025;

      5/7/25 7:00:00 AM ET
      $APLS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Apellis Pharmaceuticals to Host Conference Call on May 7, 2025, to Discuss First Quarter 2025 Financial Results

      WALTHAM, Mass., April 30, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) today announced that the company will host a conference call and webcast to discuss its first quarter 2025 financial results on Wednesday, May 7, 2025, at 8:30 a.m. ET. To access the live call by phone, please pre-register for the call here. A live audio webcast of the event and accompanying slides may also be accessed through the "Events and Presentations" page of the "Investors and Media" section of the company's website. A replay of the webcast will be available for 90 days following the event. About Apellis Apellis Pharmaceuticals, Inc. is a global biopharmaceutical company that combines co

      4/30/25 7:00:00 AM ET
      $APLS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results

      Reported $781.4 million in full year 2024 revenues, representing 97% year-over-year growth SYFOVRE® (pegcetacoplan injection) full year 2024 net product revenue of $611.9 millionEMPAVELI® (pegcetacoplan) full year 2024 net product revenue of $98.1 million Submitted a supplemental new drug application (sNDA) for approval of EMPAVELI for C3G and primary IC-MPGN; U.S. launch anticipated in 2H 2025, if approved On track to initiate two Phase 3 trials of EMPAVELI in focal segmental glomerulosclerosis (FSGS) and in delayed graft function (DGF) in 2H 2025Cash and cash equivalents of $411.3 million as of December 31, 2024; projected revenues and cash expected to be sufficient to fund operations to p

      2/28/25 7:05:00 AM ET
      $APLS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $APLS
    Leadership Updates

    Live Leadership Updates

    See more
    • Apellis Announces Craig Wheeler to Join the Board of Directors

      WALTHAM, Mass., April 21, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) today announced that Craig Wheeler, founder and chief executive officer of Headwaters Biotech Advisors, will join the Apellis Board of Directors, effective immediately. Mr. Wheeler is a highly accomplished executive with more than 30 years of leadership experience across the biopharmaceutical industry. "We are thrilled to welcome Craig to the Apellis Board of Directors," said Cedric Francois, M.D., Ph.D., chief executive officer and co-founder, Apellis. "Craig is a seasoned leader, who has successfully grown biopharmaceutical companies into strong commercial organizations with robust pipelines

      4/21/25 7:00:00 AM ET
      $APLS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cardurion Pharmaceuticals Appoints Karen Lewis as Chief People Officer

      Cardurion Pharmaceuticals, Inc. ("Cardurion"), a clinical-stage biotechnology company discovering and developing new therapeutic approaches for the treatment of cardiovascular diseases, today announced that Karen Lewis has joined the company as Chief People Officer. She joins Cardurion with more than 25 years of experience in human resources helping to build organizations and develop programs that support companies at various stages of growth. She most recently was Chief People Officer at Apellis Pharmaceuticals (NASDAQ:APLS) during a period of rapid growth, and previously held leadership roles in human resources at Biogen (NASDAQ:BIIB) and Bristol-Myers Squibb (NYSE:BMY). "We're delighted

      3/20/25 8:00:00 AM ET
      $APLS
      $BIIB
      $BMY
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Apellis Announces Keli Walbert to Join the Board of Directors

      WALTHAM, Mass., Jan. 10, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) today announced that Keli Walbert will join the Apellis Board of Directors, effective immediately. Ms. Walbert brings more than two decades of biopharmaceutical commercial leadership experience to the Board. "We are delighted to welcome Keli to the Apellis Board of Directors," said Cedric Francois, M.D., Ph.D., chief executive officer and co-founder, Apellis. "Keli has a proven track record of successfully bringing novel medicines to patients as well as a respected reputation among industry leaders for her strategic thinking and innovation. Her deep commercial expertise will be invaluable as we c

      1/10/25 7:00:00 AM ET
      $APLS
      Biotechnology: Pharmaceutical Preparations
      Health Care